X

Trial Profile

A Phase 1B Study to Evaluate the Safety and Induction of Immune Response of CRS-207 in Combination With Pemetrexed and Cisplatin as Front-line Therapy in Adults With Malignant Pleural Mesothelioma

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CRS 207 (Primary) ; Cisplatin; Cyclophosphamide; Pemetrexed
Indications Malignant-mesothelioma
Focus Adverse reactions; Pharmacodynamics
Sponsors Aduro BioTech

Most Recent Events

01 Jul 2019 Results published in the Clinical Cancer Research
08 Jan 2019 Planned End Date changed from 1 Dec 2018 to 1 Jun 2019.
08 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Jun 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com